Latest News

Glofitamab Plus Polatuzumab Shows Durable Results in R/R LBCL
Glofitamab Plus Polatuzumab Shows Durable Results in R/R LBCL

December 10th 2024

Fixed-duration glofitamab combined with polatuzumab vedotin achieved high response rates and sustained remissions in heavily pretreated relapsed/refractory large B-cell lymphoma.

BOVen Regimen Appears Effective in High-Risk MCL
BOVen Regimen Appears Effective in High-Risk MCL

October 25th 2024

Later-Line CD19 and Bispecific Therapies Considered After CAR T
Later-Line CD19 and Bispecific Therapies Considered After CAR T

October 1st 2024

From ABVD to Nivolumab-AVD: New Treatment Strategies in Hodgkin Lymphoma
From ABVD to Nivolumab-AVD: New Treatment Strategies in Hodgkin Lymphoma

September 18th 2024

Participants Discuss LOTIS-2 Data Based on Patient Case of DLBCL
Participants Discuss LOTIS-2 Data Based on Patient Case of DLBCL

September 16th 2024